Delcath Systems (DCTH) Reports Q4 Loss of $0.01/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/12/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
Delcath Announces Second Quarter 2017 Financial Results
August 8, 2017 8:30 AM EDTNEW YORK, Aug. 8, 2017 /PRNewswire/ --Â Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the three and six months ended June 30, 2017.
Highlights from the second quarter of 2017 and recent weeks include:
Revenue for the second quarter of 2017 increased 20% to $0.6 million from $0.5 million in the prior-year quarter;Â Revenue for the first six months of 2017 increased 44% to $1.3 million from $0.9 million in the prior-year period; Inclusion of CHEMOSAT in Dutch Health Authorities Guidelines (published... More